Is MAGE-1 expression in metastatic malignant melanomas really helpful?

被引:12
作者
Gajjar, NA [1 ]
Cochran, AJ [1 ]
Binder, SW [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
关键词
melanoma; MAGE-1; tyrosinase; immunotherapy;
D O I
10.1097/00000478-200407000-00006
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Melanoma antigen-encoding gene (MACE-1) has been introduced as a sensitive immunohistochemical marker to aid in the diagnosis of malignant melanomas, in particular, those that are H M B45 negative. Our goal was to determine the consistency of positive staining in melanomas on the basis of the usefulness of MACE-I in comparison with tyrosinase and MART-1. We studied 56 malignant melanomas using immunohistochemical markers to MACE-1, tyrosinase, MART-1, HMB-45, and S-100. Six of 17 HMB-45-negative cases were strongly positive for MADE-1 (35%), while 9 of 39 HMB-45-positive cases were positive for MACE-1 (23%), overall, 27% positivity (n = 56). Tyrosinase and MART-1 were both strongly positive in 42 of 56 cases (75%). Fifty-two of 56 cases were strongly positive for S-100 (93%). We found MACE-1 to be less sensitive than described in other studies, and overall, not very helpful, especially as a predictor of aggressive behavior. Although MACE-1 expression has been considered as a target for immunomodulation therapy, our findings do not indicate consistent expression of this epitope in a majority of melanomas. S-100 protein, tyrosinase, and MART-1 immunomarkers were more frequently positive in our melanoma cases and appear to constitute a useful panel of markers to aid in the diagnosis of metastatic malignant melanomas, especially in patients with an unknown primary.
引用
收藏
页码:883 / 888
页数:6
相关论文
共 25 条
[1]  
Bodey B, 2002, IN VIVO, V16, P583
[2]  
CEBON J, 1997, AUSTRALAS J DERMA S1, V38, P66
[3]  
Cheville JC, 1999, MODERN PATHOL, V12, P974
[4]  
Cochran AJ, 2000, CLIN LAB MED, V20, P759
[5]  
Corrias MV, 1996, INT J CANCER, V69, P403, DOI 10.1002/(SICI)1097-0215(19961021)69:5<403::AID-IJC9>3.0.CO
[6]  
2-9
[7]  
COULIE PG, 2002, SUPPL TUMORI S, V1, P63
[8]   Alternative promoters of gene MAGE4a [J].
DePlaen, E ;
Naerhuyzen, B ;
DeSmet, C ;
Szikora, JP ;
Boon, T .
GENOMICS, 1997, 40 (02) :305-313
[9]   Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials - A preliminary look [J].
Fetsch, PA ;
Steinberg, SM ;
Riker, AI ;
Marincola, FM ;
Abati, A .
CANCER CYTOPATHOLOGY, 2001, 93 (06) :409-414
[10]   The potential of melanoma antigen expression in cancer therapy [J].
Gillespie, AM ;
Coleman, RE .
CANCER TREATMENT REVIEWS, 1999, 25 (04) :219-227